Canada Moves To Boost Biosimilar Market
Executive Summary
Biosimilar uptake in Canada is expected to benefit from moves to switch patients onto biosimilars and the removal of health technology appraisal reviews from the process for listing drugs on public plans.
You may also be interested in...
Health Canada Ponders UK Model On Easing Biosimilar Study Requirements
Discussions are ongoing at Health Canada on the feasibility of adopting the UK model of easing clinical study requirements for biosimilars, said director general Celia Lourenco at a recent event. Meanwhile, the US FDA’s stance is unchanged for now.
Health Canada Ponders UK Model On Easing Biosimilar Study Requirements
Discussions are ongoing at Health Canada on the feasibility of adopting the UK model of easing clinical study requirements for biosimilars, said director general Celia Lourenco at a recent event. Meanwhile, the US FDA’s stance is unchanged for now.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.